Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2020 Report on Insulin Resistance R&D Pipeline Analysis - Small Insulin Resistance Companies Look for Licensing and Collaboration Partners - ResearchAndMarkets.com

April 16, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Apr 16, 2021--

The “Insulin Resistance R&D Pipeline Analysis Report, Q4 2020” report has been added to ResearchAndMarkets.com’s offering.

The Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Insulin Resistance, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.


Insulin Resistance Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Insulin Resistance disease overview, Insulin Resistance types, Insulin Resistance symptoms, causes, and FDA/EMA approved treatment options.

Insulin Resistance Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Insulin Resistance indication. The report presents near-term and long-term pipeline development trends and potential insights.

Insulin Resistance Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 8 companies. Business profiles and contact details of the companies actively perusing Insulin Resistance pipeline are assessed.

Insulin Resistance R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Insulin Resistance discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Insulin Resistance companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Insulin Resistance pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.


Insulin Resistance Pipeline Market News and Developments during 2020

The Insulin Resistance industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Insulin Resistance Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Scope and Coverage

  • Insulin Resistance pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
  • Company-company partnerships, company-institute partnerships, and investment details of companies are included
  • 8 companies are included including Amolyt Pharma, Exscien Corp, Hanmi Pharmaceuticals Co Ltd, Lixte Biotechnology Holdings Inc, Neurodon LLC, NorthSea Therapeutics BV, Pfizer Inc, Roche ,
  • Disease overview, Pipeline trends, market analysis, and other developments
  • Potential licensing/new business opportunities in Insulin Resistance pipeline market


  • Global coverage of companies and pipeline agents
  • 2020 Trends, market analysis, and developments
  • Potential growth opportunities
  • Comprehensive details of drug candidates

Reasons to Buy

  • Drive pipeline research and commercial assessment
  • Assess most promising drug candidates and stay ahead of the competition
  • Strengthen your pipeline through identifying business expansion and acquisition opportunities
  • Develop new candidates based on most focused targets and mechanism of actions


Key Topics Covered:


1. Table of Contents


2. Insulin Resistance Pipeline Trends and Insights

2.1 Dominant Phase type of Insulin Resistance Pipeline, 2020

2.2 Most focused Mechanism of Action in Insulin Resistance Pipeline

2.3 Leading type of Route of Administration during 2020

2.4 Proportion of New Molecular Entities in Insulin Resistance pipeline

2.5 Active Companies Developing Insulin Resistance pipeline


3. Insulin Resistance Disease Types, Symptoms, Causes, and Available Treatment Options

3.1 Disease Overview

3.2 Types

3.3 Symptoms

3.4 Approved Treatment Options


4. Insulin Resistance Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts

  • Amolyt Pharma
  • Exscien Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Lixte Biotechnology Holdings Inc
  • Neurodon LLC
  • NorthSea Therapeutics BV
  • Pfizer Inc
  • Roche


5. Insulin Resistance Pipeline Drug Profiles

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details


6. Insulin Resistance Pipeline Market News and Developments during 2020


7. Appendix


For more information about this report visit https://www.researchandmarkets.com/r/wwaolq.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210416005457/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 04/16/2021 01:00 PM/DISC: 04/16/2021 01:01 PM